Breast Cancer | Specialty

Role of Lapatinib in HER2-Positive Breast Cancer

January 22nd 2014

Recommendations for Optimal HER2 Testing in Breast Cancer

January 22nd 2014

T-DM1 in HER2-Positive Metastatic Breast Cancer

January 22nd 2014

PIK3CA Mutations in HER2-Positive Breast Cancer

January 22nd 2014

Frontline Pertuzumab for Metastatic Breast Cancer

January 22nd 2014

Treating Low-Risk HER2-Positive Breast Cancer

January 22nd 2014

Overview of HER2-Targeted Therapies in Breast Cancer

January 22nd 2014

Gradishar Provides Insight into New Breast Cancer Treatments

January 21st 2014

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.

Dr. Nagendran on Family History, BRCA Status, and Risk

January 20th 2014

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.

Dr. Piccart on a 4-Year Follow-Up of the NeoALTTO Trial

January 14th 2014

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

Fisher's Respect for Scientific Methods Propelled Landmark Advances

January 10th 2014

When Bernard Fisher, MD, first became involved in breast cancer research, the only treatment option available to patients was the radical mastectomy, a horribly disfiguring surgery that had been the undisputed standard of care since the late 1800s

Dr. Gradishar on Endocrine Therapy in Early Stage Disease

January 10th 2014

William J. Gradishar, MD, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the treatment of early stage breast cancer with endocrine therapy and considerations following resistance.

Dr. O'Regan on Breast Cancer Endocrine Therapy Resistance

January 8th 2014

Ruth M. O'Regan, MD, director of Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses resistance to endocrine therapy in patients with metastatic, hormone receptor-positive breast cancer.

Novel Tomography System May Help Guide Therapy in Early Breast Cancer

January 8th 2014

Diffuse optical tomography (DOT) is a novel, fast, safe, and low-cost technique that uses near-infrared light to provide three-dimensional data on tissue vascularity without the use of radiation.

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

January 3rd 2014

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Significant Changes to Reimbursement Rates in Breast Cancer for 2014

December 31st 2013

Although the changeover to using ICD-10 billing codes won't be mandatory until October 1, 2014, there are many coding changes to consider starting on January 1. Specifically, the reimbursement rate for some genetic testing and imaging involving breast cancer will see significant changes.

PI3K-Targeting Agents May Help Overcome Resistance in Breast Cancer Treatment

December 20th 2013

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.

Managing Bone Health in Advanced Lung Cancer

December 19th 2013

Managing Bone Health in Breast Cancer

December 19th 2013

Managing Bone Health in Prostate Cancer

December 19th 2013